Phase II: Safety and Primary Efficacy of Clinical Application of Newcastle Disease Virus for the Treatment of Patients Resistant to All Conventional Modalities
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and primary efficacy of NDV treatment in cancer patients who failed conventional modalities.
Shimon Slavin, MD
Hadassah Medical Organization
Israel: Israeli Health Ministry Pharmaceutical Administration